- Home
- TPG vs HALO Comparison
TPG vs HALO Comparison
Compare TPG & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPG
- HALO
- Stock Information
- Founded
- TPG 1992
- HALO 1998
- Country
- TPG United States
- HALO United States
- Employees
- TPG N/A
- HALO N/A
- Industry
- TPG Investment Managers
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TPG Finance
- HALO Health Care
- Exchange
- TPG Nasdaq
- HALO Nasdaq
- Market Cap
- TPG 8.2B
- HALO 7.6B
- IPO Year
- TPG 2022
- HALO N/A
- Fundamental
- Price
- TPG $53.34
- HALO $68.06
- Analyst Decision
- TPG Buy
- HALO Buy
- Analyst Count
- TPG 14
- HALO 11
- Target Price
- TPG $64.38
- HALO $74.91
- AVG Volume (30 Days)
- TPG 1.8M
- HALO 1.7M
- Earning Date
- TPG 11-04-2025
- HALO 11-03-2025
- Dividend Yield
- TPG 3.26%
- HALO N/A
- EPS Growth
- TPG N/A
- HALO 56.58
- EPS
- TPG N/A
- HALO 4.74
- Revenue
- TPG $4,255,344,000.00
- HALO $1,242,852,000.00
- Revenue This Year
- TPG N/A
- HALO $32.47
- Revenue Next Year
- TPG $24.79
- HALO $24.31
- P/E Ratio
- TPG N/A
- HALO $14.37
- Revenue Growth
- TPG 24.91
- HALO 31.19
- 52 Week Low
- TPG $37.52
- HALO $42.01
- 52 Week High
- TPG $72.98
- HALO $79.50
- Technical
- Relative Strength Index (RSI)
- TPG 35.43
- HALO 53.57
- Support Level
- TPG $53.76
- HALO $63.90
- Resistance Level
- TPG $58.59
- HALO $66.97
- Average True Range (ATR)
- TPG 1.74
- HALO 1.81
- MACD
- TPG -0.15
- HALO 0.26
- Stochastic Oscillator
- TPG 26.76
- HALO 69.22
About TPG TPG Inc.
TPG Inc is an alternative asset management firm. It invests across five multi-product platforms namely Capital, Growth, Impact, Real Estate, Market Solutions, and TPG Angelo Gordon. The company focuses on large-scale, control-oriented private equity investments.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.